• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why CorMedix Are Trading Lower By 22%; Here Are 20 Stocks Moving Premarket

    6/29/23 8:18:31 AM ET
    $AHG
    $BB
    $BDTX
    $BTTR
    Real Estate
    Real Estate
    Computer Software: Prepackaged Software
    Technology
    Get the next $AHG alert in real time by email

    Gainers

    • Eco Wave Power Global AB (NASDAQ:WAVE) shares surged 123% to $3.48 in pre-market trading after dropping over 8% on Wednesday.
    • Kintara Therapeutics, Inc. (NASDAQ:KTRA) shares gained 33.1% to $3.98 in pre-market trading after the company secured $2.0 million National Institutes of Health SBIR grant to support clinical development of REM-001.
    • Fangdd Network Group Ltd. (NASDAQ:DUO) shares rose 21.7% to $0.9367 in pre-market trading after dropping 11% on Wednesday. FangDD Network Group recently received Nasdaq notice regarding minimum bid price requirements.
    • BlackBerry Limited (NYSE:BB) shares rose 18.5% to $5.94 in pre-market trading after the company reported better-than-expected fiscal first-quarter results.
    • Emerson Radio Corp. (NYSE:MSN) shares gained 18.5% to $0.64 in pre-market trading.
    • Akso Health Group (NASDAQ:AHG) shares climbed 18.2% to $0.39 in pre-market trading after gaining around 5% on Wednesday.
    • Better Choice Company Inc. (NYSE:BTTR) rose 16.7% to $0.2690 in pre-market trading after declining around 8% on Wednesday. Better Choice recently announced a $5 million investment from Alphia, establishing a direct manucafturing relationship.
    • AIM ImmunoTech Inc. (NYSE:AIM) gained 15.8% to $0.6830 in pre-market trading after gaining around 5% on Wednesday. AIM ImmunoTech recently announced publication of findings from a pre-clinical study evaluating Ampligen in the treatment of pancreatic cancer in the American Journal of Cancer Research.
    • ZIVO Bioscience, Inc. (NASDAQ:ZIVO) rose 14.5% to $2.69 in pre-market trading after declining over 3% on Wednesday.
    • Shapeways Holdings, Inc. (NYSE:SHPW) gained 11.9% to $3.30 in pre-market trading after the company announced securing two new Tier 1 supplier contracts.

    Losers

    • CorMedix Inc. (NASDAQ:CRMD) fell 21.6% to $3.97 in pre-market trading after the company reported pricing of $40 million public offering of common stock and pre-funded warrants.
    • iMedia Brands, Inc. (NASDAQ:IMBI) fell 14.1% to $0.1656 in pre-market trading after jumping 20% on Wednesday.
    • Novan, Inc. (NASDAQ:NOVN) fell 13.4% to $0.3971 in pre-market after gaining over 12% on Wednesday.
    • Knightscope, Inc. (NASDAQ:KSCP) fell 11.4% to $0.6201 in pre-market trading after jumping 52% on Wednesday. The company's CEO made comments about 2023 projections on the Stock Day podcast.
    • Minerva Neurosciences, Inc. (NASDAQ:NERV) fell 10.1% to $9.16 in pre-market trading. Minerva Neurosciences shares jumped over 69% on Wednesday after the company announced a $20 million private placement priced at a premium to the market.
    • Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) shares dropped 10% to $5.16 in pre-market trading after the company reported a $75 million proposed public offering of common stock.
    • Surgalign Holdings, Inc. (NASDAQ:SRGA) shares dropped 10% to $0.27 in pre-market trading after gaining 11% on Wednesday. Surgalign Holdings’ subsidiary Holo Surgical was granted European Patent Number EP3751516 titled "Autonomous Multidimensional Segmentation Of Anatomical Structures On Three-Dimensional Medical Imaging."
    • Centogene N.V. (NASDAQ:CNTG) fell 8.9% to $1.44 in pre-market trading after jumping 34% on Wednesday. CENTOGENE and Lifera recently formed a Saudi Arabian joint venture.
    • Appreciate Holdings, Inc. (NASDAQ:SFR) fell 8.1% to $0.3739 in pre-market trading after gaining 7% on Wednesday.
    • Jaguar Health, Inc. (NASDAQ:JAGX) shares fell 7% to $0.4820 in pre-market trading. Napo Pharmaceuticals, a Jaguar Health Company, submitted investigational new drug application to the FDA for microvillus inclusion disease.

     

    Now Read This: Investor Optimism Improves After Nasdaq Settles Higher

    Get the next $AHG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHG
    $BB
    $BDTX
    $BTTR

    CompanyDatePrice TargetRatingAnalyst
    Black Diamond Therapeutics Inc.
    $BDTX
    12/3/2025Buy → Neutral
    Guggenheim
    Black Diamond Therapeutics Inc.
    $BDTX
    11/18/2025$9.00Overweight
    Piper Sandler
    CorMedix Inc.
    $CRMD
    10/20/2025$14.00Hold → Buy
    D. Boral Capital
    Black Diamond Therapeutics Inc.
    $BDTX
    10/16/2025$8.00Buy
    Stifel
    BlackBerry Limited
    $BB
    10/3/2025$5.00Buy → Hold
    TD Securities
    Black Diamond Therapeutics Inc.
    $BDTX
    9/4/2025$8.00Buy
    Guggenheim
    Black Diamond Therapeutics Inc.
    $BDTX
    7/1/2025$11.00Outperform
    Raymond James
    CorMedix Inc.
    $CRMD
    6/30/2025Buy → Hold
    D. Boral Capital
    More analyst ratings

    $AHG
    $BB
    $BDTX
    $BTTR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 17, 2023 - FDA Roundup: November 17, 2023

    For Immediate Release: November 17, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, to mark the 15th anniversary of the FDA foreign offices, the FDA published an interview with Susan Winckler, who was FDA chief of staff when the first office was opened in Beijing on November 19, 2008. Winckler is now CEO of the Reagan-Udall Foundation

    11/17/23 4:18:44 PM ET
    $BMY
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DEFENCATH issued to CORMEDIX INC

    Submission status for CORMEDIX INC's drug DEFENCATH (ORIG-1) with active ingredient TAUROLIDINE AND HEPARIN SODIUM has changed to 'Approval' on 11/15/2023. Application Category: NDA, Application Number: 214520, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

    11/15/23 9:53:06 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $BB
    $BDTX
    $BTTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Eco Wave Power Highlighted in U.S. Department of Energy National Laboratory Report Emphasizing the Strong Economic and Deployment Advantages of Coastal Structure-Integrated Wave Energy

    Los Angeles, California--(Newsfile Corp. - February 19, 2026) - Eco Wave Power Global AB (NASDAQ:WAVE) ("Eco Wave Power" or the "Company"), a leading developer of onshore wave energy technology, today announced its inclusion in a major U.S. Department of Energy ("DOE") national laboratory report emphasizing the high-value potential of Coastal Structure Integrated Wave Energy Converters ("CSI-WECs") across U.S. coastlines.The report, authored by the National Laboratory of the Rockies for the DOE Office of Energy Efficiency and Renewable Energy Water Power Technologies Office (produced while operating as the National Renewable Energy Laboratory (NREL)), evaluates the technical, economic, and g

    2/19/26 8:30:00 AM ET
    $WAVE
    Electric Utilities: Central
    Utilities

    Eco Wave Power Completes Feasibility Study for Wave Energy Project at Port of Ngqura, South Africa, with Encouraging Results

    Stockholm, Sweden--(Newsfile Corp. - February 17, 2026) - Eco Wave Power Global AB (publ) (NASDAQ:WAVE) ("Eco Wave Power" or the "Company"), a leading onshore wave energy technology company, today announced the successful completion of a feasibility study for a potential wave energy power station at the Port of Ngqura, South Africa.Africa Great Future Development Ltd (AGFDL) Team at the Port of Los Angeles OpeningTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/11247/284129_53303ee3843bb8a7_001full.jpgThe feasibility study, conducted in collaboration with Africa Great Future Development Ltd (AGFDL), delivered encouraging results, indicating the

    2/17/26 8:30:00 AM ET
    $WAVE
    Electric Utilities: Central
    Utilities

    CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering

    This press release is issued solely to correct a date from an AIM press release dated February 11, 2026. The Subscription Rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on February 27, 2026, the expected expiration date of the Rights Offering. OCALA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) – AIM ImmunoTech Inc. ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced that it has commenced its previously disclosed rights offering (the "Rights Of

    2/12/26 4:35:00 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AHG
    $BB
    $BDTX
    $BTTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Black Diamond Therapeutics downgraded by Guggenheim

    Guggenheim downgraded Black Diamond Therapeutics from Buy to Neutral

    12/3/25 12:43:23 PM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler resumed coverage on Black Diamond Therapeutics with a new price target

    Piper Sandler resumed coverage of Black Diamond Therapeutics with a rating of Overweight and set a new price target of $9.00

    11/18/25 8:20:21 AM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cormedix upgraded by D. Boral Capital with a new price target

    D. Boral Capital upgraded Cormedix from Hold to Buy and set a new price target of $14.00

    10/20/25 9:02:46 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $BB
    $BDTX
    $BTTR
    SEC Filings

    View All

    SEC Form DEF 14A filed by Emerson Radio Corporation

    DEF 14A - EMERSON RADIO CORP (0000032621) (Filer)

    2/20/26 4:15:55 PM ET
    $MSN
    Consumer Electronics/Appliances
    Consumer Staples

    SEC Form 6-K filed by Eco Wave Power Global AB

    6-K - Eco Wave Power Global AB (publ) (0001846715) (Filer)

    2/19/26 8:30:25 AM ET
    $WAVE
    Electric Utilities: Central
    Utilities

    Jaguar Health Inc. filed SEC Form 8-K: Other Events, Material Modification to Rights of Security Holders, Regulation FD Disclosure

    8-K - Jaguar Health, Inc. (0001585608) (Filer)

    2/18/26 9:01:37 AM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $BB
    $BDTX
    $BTTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Strome Mark E bought $195,400 worth of shares (20,000 units at $9.77) (SEC Form 4)

    4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

    2/17/26 6:22:38 AM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Yaldoo Laith L bought $24,997 worth of shares (2,434 units at $10.27) (SEC Form 4)

    4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

    2/12/26 9:21:50 AM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Cornell Alison A bought $99,995 worth of shares (11,709 units at $8.54), increasing direct ownership by 4% to 279,481 units (SEC Form 4)

    4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

    1/28/26 4:11:45 PM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $BB
    $BDTX
    $BTTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Strome Mark E bought $195,400 worth of shares (20,000 units at $9.77) (SEC Form 4)

    4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

    2/17/26 6:22:38 AM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Yaldoo Laith L bought $24,997 worth of shares (2,434 units at $10.27) (SEC Form 4)

    4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

    2/12/26 9:21:50 AM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Zelnick Kaufman Beth was granted 36,006 shares, increasing direct ownership by 15% to 269,108 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    2/6/26 9:30:06 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $BB
    $BDTX
    $BTTR
    Financials

    Live finance-specific insights

    View All

    AIM ImmunoTech Announces Stock Dividend

    OCALA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) --  AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced a stock dividend of one share of common stock for every 1,000 shares of outstanding common stock as well as one share of common stock for every outstanding option or warrant that has a right to receive stock dividends ("Alternate Securities"). The dividend will be issuable to stockholders and Alternate Securities holders of record at the close of business on January 9, 2026 and will be distributed and allocated to DTCC on January 13, 2026. Resulting fractional shares will be rounded down and any resulting fractional shares remaining after the foregoing rounding down will

    12/30/25 5:10:00 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

    Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no new safety signals observed to datePFS data for 1L NSCLC patients expected in Q2 2026; Company continues to explore partnership opportunities for pivotal development of silevertinibBased on encouraging CNS activity of silevertinib in multiple trials across NSCLC and GBM, Company plans to initiate a randomized Phase 2 trial of silevertinib in newly diagnosed GBM patients in 1H 2026; initial data anticipated in 2028Cash, cash equivalents, and investments of $135.5 million as of September 30, 2025;

    12/3/25 7:01:00 AM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update

    Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash and investments at September 30, 2025 were $21.3 million; combined with conditional future tranches of previous financings, expect sufficient cash through a potential PMA approval of Niyad in late 2026 5 of the 9 target profile clinical sites are now activated; completion of NEPHRO study expected in H1 2026 Conference call and webcast to be held Wednesday, November 12, 2025 at 4:30 pm ET SAN MATEO, Calif., Nov. 12, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use i

    11/12/25 4:05:00 PM ET
    $CRMD
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $BB
    $BDTX
    $BTTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Fangdd Network Group Ltd.

    SC 13G - Fangdd Network Group Ltd. (0001750593) (Subject)

    12/16/24 4:26:40 PM ET
    $DUO
    Real Estate
    Finance

    Amendment: SEC Form SC 13G/A filed by Fangdd Network Group Ltd.

    SC 13G/A - Fangdd Network Group Ltd. (0001750593) (Subject)

    12/16/24 4:24:27 PM ET
    $DUO
    Real Estate
    Finance

    $AHG
    $BB
    $BDTX
    $BTTR
    Leadership Updates

    Live Leadership Updates

    View All

    CorMedix Therapeutics Announces Leadership and Board Updates

    BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced an addition to its executive leadership team and updates to its Board of Directors. CorMedix CEO Joseph Todisco has signed an extended employment contract, reaffirming his long-term commitment to the organization. In addition to his role as CEO, Mr. Todisco will also assume the role of Chairman of the Board of Directors, succeeding Myron Kaplan. Mr. Kaplan will transition into a newly created board position of Lead Independent Director. "Under t

    1/8/26 8:05:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors

    BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the board of directors. Dr. Kaul will also serve as a consultant to the Company for the future clinical development of roluperidone. Last month, the Company announced successfully raising up to $200 million in a private placement to fund a confirmatory Phase 3 trial for roluperidone for the treatment of negative symptoms in patients with schizophrenia, resubmission of it

    11/19/25 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera Announces the Appointment of Joe Todisco to Board of Directors

    SAN MATEO, Calif., Oct. 21, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Joe Todisco, the CEO of CorMedix Inc. (NASDAQ:CRMD) to its Board of Directors. In September 2025, CorMedix made a strategic investment in Talphera as part of the company's private placement financing. In connection with the closing of this transaction, CorMedix has the right to nominate a representative to the Talphera Board of Directors. The Company also provided CorMedix with a 60-day exclusive negotiation period follo

    10/21/25 8:30:00 AM ET
    $CRMD
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care